TGF-beta inhibitors in cancer therapy: a review of the TGF-beta signal transduction pathway and current developments.

Tai SB, Yang JL, Liu PF, Chen CL

DOI: 10.17179/excli2026-9381
Published: 2026
Container: EXCLI journal
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.17179/excli2026-9381,
  title = {TGF-beta inhibitors in cancer therapy: a review of the TGF-beta signal transduction pathway and current developments.},
  author = {Tai SB and Yang JL and Liu PF and Chen CL},
  year = {2026},
  journal = {EXCLI journal},
  doi = {10.17179/excli2026-9381},
  url = {https://doi.org/10.17179/excli2026-9381}
}

RIS

TY  - JOUR
TI  - TGF-beta inhibitors in cancer therapy: a review of the TGF-beta signal transduction pathway and current developments.
AU  - Tai SB
AU  - Yang JL
AU  - Liu PF
AU  - Chen CL
PY  - 2026
JO  - EXCLI journal
DO  - 10.17179/excli2026-9381
UR  - https://doi.org/10.17179/excli2026-9381
ER  -

APA

SB, T., JL, Y., PF, L., & CL, C. (2026). TGF-beta inhibitors in cancer therapy: a review of the TGF-beta signal transduction pathway and current developments.. EXCLI journal. https://doi.org/10.17179/excli2026-9381

Source records

pubmed · retrieved 2026-09-26T17:27:46.082Z